TLSA Tiziana Life Sciences Ltd
Price Chart
Executive Summary
Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies Healthcare Conference in New York on June 4, 2026. The presentation will cover recent clinical and corporate updates, including progress on intranasal foralumab for non-active secondary progressive multiple sclerosis. This is a routine investor relations event with no new material clinical data or financial information disclosed.
Actionable Insight
Monitor the Jefferies conference presentation for any new clinical data or pipeline updates that could move the stock. The presentation may provide color on foralumab development timelines and upcoming milestones, but no material catalyst is expected from this routine conference participation alone.
Key Facts
- Tiziana Life Sciences will present at the Jefferies Healthcare Conference on June 4, 2026 in New York City.
- CEO Ivor Elrifi and COO/CFO Keeren Shah will deliver a corporate presentation highlighting recent clinical and corporate updates.
- Lead candidate intranasal foralumab is being studied in a Phase 2a trial (NCT06292923) and an Expanded Access Program (NCT06802328) in non-active secondary progressive multiple sclerosis.
- 14 patients have been dosed in the EA Program with improvement or stability of disease seen within 6 months in all patients.
- No financial results, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial data disclosed.
Risk Factors
- No new data disclosed; market may be disappointed if investors expected a more substantive update.
- Biotech sector relies heavily on clinical trial results; any negative data from ongoing trials would overshadow conference participation.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061726 |
| Document: ea029248801ex99-1.htm | 0001213900-26-061726 |
| Document: 0001213900-26-061726-index-headers.html | 0001213900-26-061726 |
| Document: 0001213900-26-061726-index.html | 0001213900-26-061726 |
| Document: 0001213900-26-061726.txt | 0001213900-26-061726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
6-K
| $1.46 $1.27 | ▼ −13.01% | ▼ −13.33% | $1.10 (−24.66%) |
|
May 21, 2026
24d ago
|
6-K
| $1.46 $1.46 | · 0.00% | ▼ −1.60% | $1.10 (−24.66%) |
|
May 21, 2026
24d ago
|
Press Release
| $1.46 $1.46 | · 0.00% | ▼ −1.60% | $1.10 (−24.66%) |
|
May 19, 2026
26d ago
|
6-K
| $1.38 $1.47 | ▲ +6.52% | ▲ +4.22% | $1.10 (−20.29%) |
|
May 14, 2026
4w ago
|
6-K
| $1.45 $1.46 | ▲ +0.69% | ▲ +1.41% | $1.10 (−24.14%) |
|
Apr 16, 2026
8w ago
|
6-K
| $1.34 $1.23 | ▼ −8.21% | ▼ −9.19% | $1.10 (−17.91%) |
|
Apr 16, 2026
8w ago
|
Press Release
| $1.34 $1.23 | ▼ −8.21% | ▼ −9.19% | $1.10 (−17.91%) |
|
Apr 14, 2026
8w ago
|
6-K
| $1.29 $1.23 | ▼ −4.65% | ▼ −6.05% | $1.10 (−14.73%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.29 $1.23 | ▼ −4.65% | ▼ −6.05% | $1.10 (−14.73%) |
|
Apr 1, 2026
10w ago
|
6-K
| $1.25 $1.26 | ▲ +0.80% | ▼ −2.97% | $1.10 (−12.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access